Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

First, they can be used to exclude peptic injury as a cause for this histological finding ... Second, some patients with well-defined EoE may have an element of peptic disease and require acid ...

BOSTON (Oct. 24, 2024) – Eosinophilic Esophagitis (EoE), a disorder of the esophagus, is increasingly recognized as a major cause of swallowing difficulties in children and adults. It affects ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

In connection with the closing of the Private Placement, the Company also announces that it has terminated the Company's C$12 million convertible debt facility (the "Convertible Debt Facility"). The ...

The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, m ...

Maggie Akers’ parents knew she was failing to thrive as an infant, but they didn’t know why. Eating was clearly a painful ...

Refractory esophagitis suggests that they have a pill injury, an autoimmune skin disease with associated esophageal involvement, or eosinophilic esophagitis. Less likely causes of their symptoms ...